Renovaro completes acquisition of Biosymetrics, issues 15M shares

Lunai Bioworks Inc.

Consummated merger with Biosymetrics on April 8, 2025; Biosymetrics becomes wholly owned subsidiary.
Issued 15.0 million shares of Renovaro common stock to former Biosymetrics stockholders.
Shares issued in reliance on Section 4(a)(2) exemption based on accredited investor representations.
Transaction was previously announced on February 26, 2025 via Merger Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.